Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses
Description
Treatment options for COVID-19 remain limited. Here, we report the optimization of an siRNA targeting the highly conserved leader region of SARS-CoV-2. The siRNA was rendered nuclease resistant by the introduction of modified nucleotides without loss
